{
    "id": "5e44c59848dab47f26000021",
    "question": "Should tirilazad be used for treatment of ischemic stroke?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"Tirilazad mesylate, also known as U-74389AA, is a monoclonal antibody fragment that targets the alpha-2 vasoconstrictor receptor. It is used to reduce cerebral blood flow in certain conditions, such as subarachnoid hemorrhage. However, its use in ischemic stroke treatment is limited due to concerns about its safety and efficacy.\\n\\nIn clinical trials, tirilazad mesylate did not demonstrate a significant benefit in improving outcomes in patients with acute ischemic stroke. In fact, the trial data showed a higher risk of intracerebral hemorrhage with its use.\\n\\nAs a result, the use of tirilazad mesylate for the treatment of ischemic stroke is not recommended by current medical guidelines, and it is not approved for this indication in most countries. The American Heart Association and other professional organizations have stated that there is insufficient evidence to support its use in this context.\\n\\nTherefore, the correct answer is B. no.\", \"answer_choice\": \"B\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 20.034468173980713
}